- Home
- CWD vs BIAF Comparison
CWD vs BIAF Comparison
Compare CWD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- BIAF
- Stock Information
- Founded
- CWD 2009
- BIAF 2014
- Country
- CWD United States
- BIAF United States
- Employees
- CWD N/A
- BIAF N/A
- Industry
- CWD Real Estate
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CWD Finance
- BIAF Health Care
- Exchange
- CWD Nasdaq
- BIAF Nasdaq
- Market Cap
- CWD 12.1M
- BIAF 12.2M
- IPO Year
- CWD 2023
- BIAF 2022
- Fundamental
- Price
- CWD $0.50
- BIAF $0.75
- Analyst Decision
- CWD
- BIAF Hold
- Analyst Count
- CWD 0
- BIAF 1
- Target Price
- CWD N/A
- BIAF N/A
- AVG Volume (30 Days)
- CWD 244.5K
- BIAF 28.2M
- Earning Date
- CWD 03-31-2025
- BIAF 05-14-2025
- Dividend Yield
- CWD N/A
- BIAF N/A
- EPS Growth
- CWD N/A
- BIAF N/A
- EPS
- CWD N/A
- BIAF N/A
- Revenue
- CWD $51,119,000.00
- BIAF $9,362,022.00
- Revenue This Year
- CWD N/A
- BIAF $25.19
- Revenue Next Year
- CWD $33.62
- BIAF $20.00
- P/E Ratio
- CWD N/A
- BIAF N/A
- Revenue Growth
- CWD N/A
- BIAF 269.68
- 52 Week Low
- CWD $0.37
- BIAF $0.24
- 52 Week High
- CWD $1.05
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- CWD 38.38
- BIAF 60.32
- Support Level
- CWD $0.48
- BIAF $0.24
- Resistance Level
- CWD $0.68
- BIAF $1.55
- Average True Range (ATR)
- CWD 0.09
- BIAF 0.13
- MACD
- CWD -0.01
- BIAF 0.08
- Stochastic Oscillator
- CWD 8.46
- BIAF 38.64
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.